Therefore, another drug, obeticholic acid (OCA), is used in patients who are unresponsive or intolerant to UDCA; however, only 50% of patients are responsive.6,7 Those who do not respond to UDCA and/or OCA medication are in danger of progressing to biliary cirrhosis, end-stage liver disease, or even death.8 Therefore, some novel therapies, including fibroblast growth factor 19 (FGF-19) analogues and nuclear and membrane receptor agonists, have been widely studied.9 This evidence concerns the gene FGF19 and biliary liver cirrhosis.